Stay updated on iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial
Sign up to get notified when there's something new on the iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial page.

Latest updates to the iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial page
- Check2 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2. No user-facing content or study information appears to be affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check10 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1; no substantive study details, outcomes, or eligibility information appear to be affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check17 days agoChange DetectedThe page now shows a glossary toggle, updates the QC label from 'Last Update' to 'Last Update Submitted that Met QC Criteria', standardizes the No FEAR Act Data wording, and updates the revision from v3.3.4 to v3.4.0.SummaryDifference0.2%

- Check32 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4; no substantive study content appears to be changed.SummaryDifference0.1%

- Check53 days agoChange DetectedThe page now displays a new footer revision tag 'Revision: v3.3.3'. The previous 'Revision: v3.3.2' tag and the 'HHS Vulnerability Disclosure' link were removed.SummaryDifference0.1%

- Check82 days agoChange DetectedAdded a note that publications are automatically filled from PubMed, and updated the page revision indicator from v3.2.0 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the iRECIST DCR Evaluation in MMR/MSI CRC on Nivolumab+Ipilimumab Clinical Trial page.